|
Volumn 13, Issue 9, 2011, Pages 597-598
|
HER2 in gastric cancer: A biomarker with clinical impact, but not without translational challenges
|
Author keywords
[No Author keywords available]
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
FLUOROURACIL;
TRASTUZUMAB;
TUMOR MARKER;
ADVANCED CANCER;
CANCER COMBINATION CHEMOTHERAPY;
COST BENEFIT ANALYSIS;
DRUG EFFICACY;
DRUG TARGETING;
EDITORIAL;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENE AMPLIFICATION;
GENE OVEREXPRESSION;
GENETIC ALGORITHM;
GENETIC MARKER;
HEALTH CARE COST;
HUMAN;
IMMUNOHISTOCHEMISTRY;
MEDICAL DECISION MAKING;
MOLECULARLY TARGETED THERAPY;
ONCOGENE NEU;
PROTEIN EXPRESSION;
QUALITY OF LIFE;
STOMACH CANCER;
TUMOR BIOPSY;
CARCINOMA;
CONSENSUS;
GENETIC SCREENING;
GENETICS;
METHODOLOGY;
NOTE;
PROTO ONCOGENE;
STOMACH TUMOR;
UTILIZATION REVIEW;
CARCINOMA;
CONSENSUS;
GENES, ERBB-2;
GENETIC TESTING;
HUMANS;
STOMACH NEOPLASMS;
|
EID: 84855361780
PISSN: 1699048X
EISSN: 16993055
Source Type: Journal
DOI: 10.1007/s12094-011-0704-z Document Type: Editorial |
Times cited : (5)
|
References (6)
|